<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Pharmacy Blog &#187; Osteoporosis</title>
	<atom:link href="http://www.canadiannetmall.com/blog/category/osteoporosis/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.canadiannetmall.com/blog</link>
	<description></description>
	<lastBuildDate>Thu, 09 Sep 2010 08:49:23 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Hylan for Ankle and Shoulder Osteoarthritis in Europe</title>
		<link>http://www.canadiannetmall.com/blog/hylan-for-ankle-and-shoulder-osteoarthritis-in-europe/</link>
		<comments>http://www.canadiannetmall.com/blog/hylan-for-ankle-and-shoulder-osteoarthritis-in-europe/#comments</comments>
		<pubDate>Sat, 03 Jul 2010 16:54:04 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[Ankle]]></category>
		<category><![CDATA[Hylan]]></category>
		<category><![CDATA[Osteoarthritis]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=3493</guid>
		<description><![CDATA[Genzyme Corporation has received European approval to expand the CE Mark labeling for hylan G-F 20 (Synvisc) to include the treatment of pain resulting from osteoarthritis (OA) of the ankle and shoulder. The CE Mark is mandatory for 70% of the products sold in Europe.
Synvisc is sold in more than 60 countries and is approved [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/hylan-for-ankle-and-shoulder-osteoarthritis-in-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Single-Dose Reclast For Preventing Osteoporosis</title>
		<link>http://www.canadiannetmall.com/blog/single-dose-reclast-for-preventing-osteoporosis/</link>
		<comments>http://www.canadiannetmall.com/blog/single-dose-reclast-for-preventing-osteoporosis/#comments</comments>
		<pubDate>Wed, 20 Jan 2010 15:07:34 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[Women's health]]></category>
		<category><![CDATA[Osteoporosis treatment]]></category>
		<category><![CDATA[postmenopausal]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=2697</guid>
		<description><![CDATA[Zoledronic acid injection (Reclast, Novartis) has been approved as the first therapy to prevent postmenopausal osteoporosis for two years with a single dose.
In a study involving more than 500 postmenopausal women with osteopenia, a single infusion significantly increased bone mineral density at two years compared with placebo.
Reclast is already approved as a once-yearly infusion to [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/single-dose-reclast-for-preventing-osteoporosis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
